Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.

Lambracht-Washington D, Fu M, Frost P, Rosenberg RN.

Alzheimers Res Ther. 2017 Apr 26;9(1):30. doi: 10.1186/s13195-017-0257-7.

2.

Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer.

Lambracht-Washington D, Fu M, Wight-Carter M, Riegel M, Rosenberg RN.

J Alzheimers Dis. 2017;57(1):97-112. doi: 10.3233/JAD-160947.

3.

A noninflammatory immune response in aged DNA Aβ42-immunized mice supports its safety for possible use as immunotherapy in AD patients.

Lambracht-Washington D, Rosenberg RN.

Neurobiol Aging. 2015 Mar;36(3):1274-81. doi: 10.1016/j.neurobiolaging.2014.12.011. Epub 2014 Dec 12.

4.

Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Aβ42 immunotherapy.

Lambracht-Washington D, Rosenberg RN.

J Neuroimmunol. 2015 Jan 15;278:90-9. doi: 10.1016/j.jneuroim.2014.12.007. Epub 2014 Dec 10.

5.

A new DNA vaccine fused with the C3d-p28 induces a Th2 immune response against amyloid-beta.

Guo W, Sha S, Jiang T, Xing X, Cao Y.

Neural Regen Res. 2013 Sep 25;8(27):2581-90. doi: 10.3969/j.issn.1673-5374.2013.27.010.

6.

Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease.

Lambracht-Washington D, Rosenberg RN.

Immunotargets Ther. 2013 Aug 1;2013(2):105-114.

7.

Stability of clinical etiologic diagnosis in dementia and mild cognitive impairment: results from a multicenter longitudinal database.

Koepsell TD, Gill DP, Chen B.

Am J Alzheimers Dis Other Demen. 2013 Dec;28(8):750-8. doi: 10.1177/1533317513504611.

8.

Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease.

Lambracht-Washington D, Rosenberg RN.

Transl Neurosci. 2012 Dec 1;3(4):307-313.

9.

Advances in the development of vaccines for Alzheimer's disease.

Lambracht-Washington D, Rosenberg RN.

Discov Med. 2013 May;15(84):319-26.

10.

DNA Aβ42 vaccination as possible alternative immunotherapy for Alzheimer disease.

Rosenberg RN, Lambracht-Washington D.

JAMA Neurol. 2013 Jun;70(6):772-3. doi: 10.1001/jamaneurol.2013.1502. Review. No abstract available.

11.

A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.

Lambracht-Washington D, Qu BX, Fu M, Anderson LD Jr, Eagar TN, Stüve O, Rosenberg RN.

J Neuroimmunol. 2013 Jan 15;254(1-2):63-8. doi: 10.1016/j.jneuroim.2012.09.008. Epub 2012 Oct 1.

12.

Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics.

Cacabelos R, Martínez R, Fernández-Novoa L, Carril JC, Lombardi V, Carrera I, Corzo L, Tellado I, Leszek J, McKay A, Takeda M.

Int J Alzheimers Dis. 2012;2012:518901. doi: 10.1155/2012/518901. Epub 2012 Mar 14.

13.

DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.

Lambracht-Washington D, Qu BX, Fu M, Anderson LD Jr, Stüve O, Eagar TN, Rosenberg RN.

Cell Mol Neurobiol. 2011 Aug;31(6):867-74. doi: 10.1007/s10571-011-9680-7. Epub 2011 Apr 6.

14.

Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease.

Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN.

Vaccine. 2010 Jul 19;28(32):5280-7. doi: 10.1016/j.vaccine.2010.05.054. Epub 2010 Jun 4.

15.

Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis.

Mondragón-Rodríguez S, Basurto-Islas G, Lee HG, Perry G, Zhu X, Castellani RJ, Smith MA.

Expert Rev Neurother. 2010 May;10(5):683-91. doi: 10.1586/ern.10.27. Review.

16.

Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.

Cribbs DH.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):207-16. Review.

Supplemental Content

Support Center